Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eciskafusp alfa + BCG in BCG-unresponsive high-risk NMIBC
2024-515410-41-00Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2025
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, open-label trial of eciskafusp alfa in bladder cancer (3 arms), sponsored by Roche. Primary endpoints: Incidence, nature, and severity of adverse events (Phase I), Dose-limiting toxicities (DLTs) (Phase I) and 2 more. Started Mar 2025; status: completed.
02
Drugs
eciskafusp alfa
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2024-515410-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515410-41-00.